Orlistat

Product Description

Orlistat is a hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A₂, liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G₁/S boundary in vitro. Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo. Orlistat inhibits neutral lipid lipase LIPE and dose-dependently reduces α-synuclein-positive cytoplasmic inclusions in α-synuclein-expressing neuroblastoma cell lines.

Solubility

Preparing Stock Solutions for Orlistat

The following data is based on the product molecular weight 495.73

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.02 mL	10.09 mL	20.17 mL
5 mM	0.40 mL	2.02 mL	4.03 mL
10 mM	0.20 mL	1.01 mL	2.02 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Fanning Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy. NPJ Parkinsons Dis. 2022 PMID: 35680956
• Kridel Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 PMID: 15026345
• Enc Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am.J.Physiol.Gastrointest.Liver Physiol. 2008 PMID: 19109408
• Hadvary The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J.Biol.Chem. 1991 PMID: 1899234